Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Hepatology (Baltimore, Md.)|June 29, 2016
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infectionArmand Abergel, Sophie Metivier, Didier Samuel, et al.Journal of Medical Virology|March 13, 2019
Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infectionRui Huang, Huiying Rao, Qing Xie, et al.Annals of the Rheumatic Diseases|November 6, 2021
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 yearsKevin L Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, et al.Journal of Hepatology|May 5, 2015
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4Wahid Doss, Gamal Shiha, Mohamed Hassany, et al.Journal of Hepatology|November 28, 2012
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trialMaribel Rodriguez-Torres, Eric Lawitz, Kris V Kowdley, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 4, 2018
Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infectionYasuhiro Asahina, Yoshito Itoh, Yoshiyuki Ueno, et al.Journal of Hepatology|December 3, 2014
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestryPeter J Ruane, Dani Ain, Richard Stryker, et al.Modern Rheumatology|April 2, 2022
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 yearsNaoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, et al.Hepatology International|July 22, 2018
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antiviralsNamiki Izumi, Tetsuo Takehara, Kazuaki Chayama, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2021
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks PosttreatmentChun Jen Liu, I Shyan Sheen, Chi Yi Chen, et al.Pageof 3